Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. We are the first biotech company to achieve psilocybin orphan drug designation in both the United States and European Union. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome. CSE: NOVA | OTCQB: NMLSF | FSE: HN3Q